Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 4.2 EX-4.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 16.1 EX-16.1
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- COVER Cover
TRAW similar filings
Filing view
External links
Exhibit 16.1
June 14, 2013
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
RE: | Onconova Therapeutics, Inc. |
| File No: 377-00169 |
Ladies and Gentleman:
We have read Onconova Therapeutics, Inc.’s statements regarding our dismissal as principal accountants, included under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” within the Form S-1 Registration Statement to be filed on or about June 14, 2013 and we agree with such statements.
Very truly yours,
/s/ EISNERAMPER LLP